Showing 1471-1480 of 5603 results for "".
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
https://reachmd.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Targeting CD19 in Autoimmune Neuropathy: Case Report Insights
https://reachmd.com/programs/living-rheum/Targeting-CD19-in-Autoimmune-Neuropathy-Case-Report-Insights/32814/PH Management in Unique Patients and Conditions
https://reachmd.com/programs/cme/ph-management-in-unique-patients-and-conditions/36096/Experts discuss addressing challenges that may come with managing patients with pulmonary hypertension (PH) in unique patient populations and with complex conditions.Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
https://reachmd.com/programs/cme/emerging-and-practice-changing-data-in-immunotherapy-strategies-for-melanoma/36330/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
https://reachmd.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
https://reachmd.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Individualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
https://reachmd.com/programs/neurofrontiers/individualized-cognitive-stimulation-mild-alzheimers/40001/A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway
https://reachmd.com/programs/cme/a-novel-therapeutic-approach-in-myeloid-malignancies-targeting-the-neddylation-pathway/11694/Learn about emerging NEDD8-activating enzyme inhibitors in myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).